Findings

What do systematic reviews say?

360 questions · 382 findings · 30 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 50 · 13.1%GRADE not reported 40 · 10.5%Very low 64 · 16.8%Low 104 · 27.2%Moderate 97 · 25.4%High 27 · 7.1%

Intervention not reported

MD‐ICS/LAMA (Direct evidence; 4 RCTs; 2239 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2239 participants
Moderate

Intervention not reported

MD‐ICS/LABA (Direct evidence; 21 RCTs; 20326 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
21 studies · 20326 participants
High

Intervention not reported

HD‐ICS/LABA (Direct evidence; 4 RCTs; 2750 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 2750 participants
High

Intervention not reported

MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

The review found no eligible studies for this question.

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

MD‐ICS/LABA (Direct evidence; 10 RCTs; 15,651 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
10 studies · 15651 participants
Moderate

Intervention not reported

HD‐ICS/LABA (Direct evidence; 3 RCTs; 3319 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3319 participants
Low

Intervention not reported

MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

The review found no eligible studies for this question.

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Total studies: 25 RCTs Total participants: 25,583 · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
25 studies · 25583 participants
GRADE not reported

Intervention not reported

HD‐ICS (Direct evidence; 4 RCTs; 1685 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…

1 finding from 1 review

Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of inhaled… 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1685 participants
Moderate

Intervention not reported

Total studies: 8 RCTs Total Participants: 9983 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 9983 participants
GRADE not reported

Intervention not reported

Total studies: 13 RCTs Total Participants: 144476 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
13 studies · 144476 participants
GRADE not reported

Intervention not reported

HD‐ICS/LABA (Direct evidence; 8 RCTs; 7511 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 7511 participants
High

Intervention not reported

MD‐TRIPLE (Direct evidence; 3 RCTs; 3187 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3187 participants
Moderate

Intervention not reported

HD‐TRIPLE (Direct evidence; 2 RCT; 2039 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2039 participants
Moderate

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Total studies: 11 RCTs Total Participants: 13209 · Adolescent sand adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 13209 participants
GRADE not reported

Intervention not reported

HD‐ICS/LABA (Direct evidence; 6 RCTs; 6244 participants) · Adolescent sand adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 6244 participants
High

Intervention not reported

MD‐TRIPLE (Direct evidence; 3 RCTs; 3188 participants) · Adolescent sand adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3188 participants
Moderate

Intervention not reported

HD‐TRIPLE (Direct evidence; 2 RCTs; 2039 participants) · Adolescent sand adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2039 participants
High

Intervention not reported

MD‐ICS/LABA · Adolescent sand adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found